Phibro Animal Health reported fiscal Q1 2027 revenue of $386.8 million, topping consensus estimates that ranged between $375.4 million and $382.24 million. The company delivered an adjusted earnings per share of $0.79, outpacing the consensus analyst estimate of $0.77.
Financial Metrics And Guidance
Management reiterated its full-year fiscal 2027 guidance, projecting an adjusted earnings per share between $3.41 and $3.59 alongside revenue of $1.55 billion to $1.60 billion. At the time of the financial report, the stock traded at $39.43 a share.
- $386.8 million in fiscal Q1 2027 revenue
- $0.79 in adjusted earnings per share
- $3.41 to $3.59 projected full-year fiscal 2027 EPS
- $1.55 billion to $1.60 billion projected full-year revenue
Segment Drivers And Offsets
Growth for the quarter was primarily anchored by the Mineral Nutrition and Performance Products segments. Meanwhile, the core Animal Health segment posted a growth rate of 3 percent during the period.
- 3 percent growth in the core Animal Health segment
- $5.2 million decline in Brazil virginiamycin sales
The segment gains were partially offset by a $5.2 million drop in virginiamycin sales in Brazil, which executives attributed to recent regulatory developments. Market participants continue to evaluate these headwinds against broader valuation and growth prospects for the livestock and companion animal nutrition provider.